(Q33919546)

30 July 2017

1 reference

title

Basis for effective combination cancer chemotherapy with antimetabolites (English)

1 reference

30 July 2017

1 reference

G J Peters

1

1 reference

30 July 2017

C L van der Wilt

2

1 reference

30 July 2017

C J van Moorsel

3

1 reference

30 July 2017

J R Kroep

4

1 reference

30 July 2017

A M Bergman

5

1 reference

30 July 2017

S P Ackland

6

1 reference

30 July 2017

1 August 2000

1 reference

Pharmacology & Therapeutics

30 July 2017

1 reference

30 July 2017

87

1 reference

30 July 2017

227-253

1 reference

30 July 2017

2-3

1 reference

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

The current role of radiotherapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Ongoing and unsaid on oxaliplatin: the hope

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

New drugs in non-small cell lung cancer. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Biochemical modulation of cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

An overview of adjuvant therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

A quantitative assay for fragmented DNA in apoptotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Biochemical pharmacology of the lipophilic antifolate, trimetrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Fluorouracil Combined With the Pure (6S)-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients With Advanced Colorectal Carcinoma: A Phase I-II Study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Nucleoside transport and its significance for anticancer drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Radiosensitizing nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Enhancement of the antitumor effects of 5-fluorouracil by folinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Clinical relevance of biochemical modulation of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Intravenous mercaptopurine: life begins at 40.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Acute lymphoblastic leukemia in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Characteristics of thymidylate synthase purified from a human colon adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Postconfluent multilayered cell line cultures for selective screening of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Current role of chemotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900086-3

7 January 2021

10.1016/S0163-7258(00)00086-3

Identifiers

DOI

1 reference

30 July 2017

1 reference